78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC).

Authors :: Oh, D-Y.
He, A.R.
Qin, S.
Chen, L-T.
Okusaka, T.
Vogel, A.
Kim, J.W.
Lee, T.
Lee, M.A.
Kitano, M.
Burris, H.A.
Bouattour, M.
Tanasanvimon, S.
Zaucha, R.E.
Avallone, A.
Cundom, J.E.
Rokutanda, N.
Żotkiewicz, M.
Cohen, G.
Valle, J.W.
Source :: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1462-S1463. 2p.
Publication Year :: 2022

Subjects :: *OVERALL survival
*CISPLATIN
*GEMCITABINE
*PLACEBOS
BILIARY tract cancer

Full Text Access

Tools